138 related articles for article (PubMed ID: 9575338)
1. Activation of cytotoxic T cells by solid tumours?
Speiser DE; Ohashi PS
Cell Mol Life Sci; 1998 Mar; 54(3):263-71. PubMed ID: 9575338
[TBL] [Abstract][Full Text] [Related]
2. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction.
Ochsenbein AF; Sierro S; Odermatt B; Pericin M; Karrer U; Hermans J; Hemmi S; Hengartner H; Zinkernagel RM
Nature; 2001 Jun; 411(6841):1058-64. PubMed ID: 11429607
[TBL] [Abstract][Full Text] [Related]
3. Tumor resistance to CD8+ T cell-based therapeutic vaccination.
Huang Y; Shah S; Qiao L
Arch Immunol Ther Exp (Warsz); 2007; 55(4):205-17. PubMed ID: 17659376
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy II: Antigens, receptors and costimulation.
Searle PF; Young LS
Cancer Metastasis Rev; 1996 Sep; 15(3):329-49. PubMed ID: 9034595
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic use of a long-term cytotoxic T cell line recognizing a common tumour-associated antigen: the pattern of in vitro reactivity predicts the in vivo effect on different tumours.
Rodolfo M; Bassi C; Salvi C; Parmiani G
Cancer Immunol Immunother; 1991; 34(1):53-62. PubMed ID: 1760812
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms and biological significance of CTL avidity.
Snyder JT; Alexander-Miller MA; Berzofskyl JA; Belyakov IM
Curr HIV Res; 2003 Jul; 1(3):287-94. PubMed ID: 15046253
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic T cells swarm by homotypic chemokine signalling.
Galeano Niño JL; Pageon SV; Tay SS; Colakoglu F; Kempe D; Hywood J; Mazalo JK; Cremasco J; Govendir MA; Dagley LF; Hsu K; Rizzetto S; Zieba J; Rice G; Prior V; O'Neill GM; Williams RJ; Nisbet DR; Kramer B; Webb AI; Luciani F; Read MN; Biro M
Elife; 2020 Oct; 9():. PubMed ID: 33046212
[TBL] [Abstract][Full Text] [Related]
8. Suppression of murine tumour growth through CD8
Kogo H; Shimizu M; Negishi Y; Uchida E; Takahashi H
Immunology; 2017 Jul; 151(3):324-339. PubMed ID: 28294313
[TBL] [Abstract][Full Text] [Related]
9. Evasion of tumours from the control of the immune system: consequences of brief encounters.
Al-Tameemi M; Chaplain M; d'Onofrio A
Biol Direct; 2012 Sep; 7():31. PubMed ID: 23009638
[TBL] [Abstract][Full Text] [Related]
10. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer.
Finn OJ
Ann Oncol; 2012 Sep; 23 Suppl 8(Suppl 8):viii6-9. PubMed ID: 22918931
[TBL] [Abstract][Full Text] [Related]
11. A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target.
Seung S; Urban JL; Schreiber H
J Exp Med; 1993 Sep; 178(3):933-40. PubMed ID: 8394406
[TBL] [Abstract][Full Text] [Related]
12. Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer.
Jäger D; Jäger E; Knuth A
J Clin Pathol; 2001 Sep; 54(9):669-74. PubMed ID: 11533070
[TBL] [Abstract][Full Text] [Related]
13. In situ activation of syngeneic tumour-specific cytotoxic T lymphocytes: intra-pinna immunization followed by restimulation in the peritoneal cavity.
Schirrmacher V; Leidig S; Griesbach A
Cancer Immunol Immunother; 1991; 33(5):299-306. PubMed ID: 1868488
[TBL] [Abstract][Full Text] [Related]
14. Intraocular tumor antigen drains specifically to submandibular lymph nodes, resulting in an abortive cytotoxic T cell reaction.
Boonman ZF; van Mierlo GJ; Fransen MF; Franken KL; Offringa R; Melief CJ; Jager MJ; Toes RE
J Immunol; 2004 Feb; 172(3):1567-74. PubMed ID: 14734736
[TBL] [Abstract][Full Text] [Related]
15. H-2 antigens and tumour-associated transplantation antigens in clones derived from a methylcholanthrene-induced BALB/c tumour: their influence on the generation in vitro and in vivo of the specific anti-tumour immune response.
Pérez M; Garrido A; Algarra I; Caballero A; Delgado C; Collado MD; Fernández-Cruz E; Garrido F
Exp Clin Immunogenet; 1989; 6(3):204-18. PubMed ID: 2631798
[TBL] [Abstract][Full Text] [Related]
16. Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines?
Coulie PG
Mol Med Today; 1997 Jun; 3(6):261-8. PubMed ID: 9211417
[TBL] [Abstract][Full Text] [Related]
17. Cloned cytotoxic T lymphocyte target cells fail to induce early activation events in effector cytotoxic T lymphocytes.
Ostergaard H; Gorman K; Clark WR
Cell Immunol; 1988 Jun; 114(1):188-97. PubMed ID: 3259474
[TBL] [Abstract][Full Text] [Related]
18. Tumors with reduced expression of a cytotoxic T lymphocyte recognized antigen lack immunogenicity but retain sensitivity to lysis by cytotoxic T lymphocytes.
Koeppen H; Acena M; Drolet A; Rowley DA; Schreiber H
Eur J Immunol; 1993 Nov; 23(11):2770-6. PubMed ID: 8223853
[TBL] [Abstract][Full Text] [Related]
19. Long-lived fusions of human haematological tumour cells and B-lymphoblastoid cells induce tumour antigen-specific cytotoxic T-cell responses in vitro.
Mohamed YS; Dunnion D; Teobald I; Walewska R; Browning MJ
Immunobiology; 2012 Jul; 217(7):719-29. PubMed ID: 22305004
[TBL] [Abstract][Full Text] [Related]
20. Review: the application of dendritic cell-derived exosomes in tumour immunotherapy.
Quah B; O'Neill HC
Cancer Biother Radiopharm; 2000 Apr; 15(2):185-94. PubMed ID: 10803324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
